Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in Advanced Melanoma
NCT06941818Phase 1Completed
- Sponsor
- Huasai Biomedicine
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-IT101 in melanoma, sponsored by Huasai Biomedicine. Primary endpoints: Adverse Events at 12 months, Serious Adverse Events at 12 months and 6 more. Started Jul 2025; status: completed.
02
Drugs
HS-IT101
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06941818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941818.